FusionPlex Core Solid Tumor is a research assay for targeted next generation sequencing of RNA for characterization of variants, indels, and fusions, including novel fusions, from 57 genes associated with various solid tumor malignancies.
FusionPlex Core Solid Tumor is a research assay for targeted next generation sequencing of RNA for characterization of variants, indels, and fusions, including novel fusions, from 57 genes associated with various solid tumor malignancies.
FusionPlex Pan Solid V2 is a research assay for targeted next generation sequencing of RNA for characterization of variants, indels, and fusions, including novel fusions, from 137 genes associated with various solid tumor malignancies.
VariantPlex Solid Tumor Focus V2 is a research assay for targeted next generation sequencing of DNA for characterization of SNVs, indels, CNVs, and MSI from 20 genes associated with various solid tumor malignancies.
VariantPlex Core Solid Tumor is a research assay for targeted next generation sequencing of DNA for characterization of SNVs, indels, CNVs, and MSI from 60 genes associated with various solid tumor malignancies.
VariantPlex Expanded Solid Tumor is a research assay for targeted next generation sequencing of DNA for characterization of SNVs, indels, CNVs, and MSI from 76 genes associated with various solid tumor malignancies.
VariantPlex Pan Solid Tumor is a research assay for targeted next generation sequencing of DNA for characterization of SNVs, indels, CNVs, MSI, and TMB from 185 genes associated with various solid tumor malignancies.
VariantPlex Complete Solid Tumor is a research assay for targeted next generation sequencing of DNA for characterization of SNVs, indels, CNVs, MSI, and TMB from 430 genes associated with various solid tumor malignancies.
Immunoverse is a research assay that characterizes the immune repertoire, including assessment of T- and B-cell clonalities and rare clones, and detection of tumor infiltrating lymphocytes (TIL) and somatic hypermutation with targeted NGS of key T cell receptor and B cell receptor chain RNA relevant for blood cancer and solid tumor research.
VariantPlex Myeloid is a research assay for targeted next generation sequencing of DNA for characterization of SNVs, indels, CNVs, and ITDs from 75 genes associated with acute myeloid leukemia (AML), myeloproliferative neoplasms (MPN), myelodysplastic syndromes (MDS).
VariantPlex Core Myeloid is a research assay for targeted next generation sequencing of DNA for characterization of SNVs, indels, CNVs, and ITDs from 37 genes associated with acute myeloid leukemia (AML), myeloproliferative neoplasms (MPN), myelodysplastic syndromes (MDS).
FusionPlex Pan Heme is a research assay for targeted next generation sequencing of RNA for characterization of variants, indels, expression, and fusions, including novel fusions, from 199 genes associated with lymphoid and myeloid malignancies.
FusionPlex Heme V2 is a research assay for targeted next generation sequencing of RNA for characterization of variants, indels, expression, and fusions, including novel fusions, from 87 genes associated with lymphoid and myeloid malignancies.
FusionPlex Myeloid is a research assay for targeted next generation sequencing of RNA for characterization of variants, indels, expression, and fusions, including novel fusions, from 84 genes associated with myeloid-origin malignancies.
FusionPlex Lymphoma is a research assay for targeted next generation sequencing of RNA for characterization of variants, indels, expression, and fusions, including novel fusions, from 125 genes associated with lymphomas.
FusionPlex ALL is a research assay for targeted next generation sequencing of RNA for characterization of variants, indels, expression, and fusions, including novel fusions, from 81 genes associated with acute lymphoblastic leukemia (ALL) .
In-depth understanding of complete genome in human, aninal, plant and microbe with end-to-end services.
Sequencing only service for customer-premade libraries at different read lengths and capacities to suit any cost, project scale and turnaround with the world-leading, powerful, and sophisticated sequencing platforms (Illumina, Pacbio, and Oxford Nanopore).
16S/18S/ITS rRNA amplicon metagenomic sequencing employs universal primers to target specific regions to identify the phylogeny and taxonomy from complex microbiomes.
Single cell RNA sequencing uncovers the complexity of cellular diversity to employ the study of unusual cell types, cell-lineage associations, and samples of heterogeneous nature with 10x Genomics technology.
As the framework of stellar automation, Nucleus® Automation Infrastructure combines (A) your choice of stationary or mobile mounted collaborative robotic arms; (B) mobile cart or stationary table work surfaces to house your preferred devices; and (C) powerful Cellario™ Whole Lab Automation software. Unique MicroDock technology lets you effortlessly roll workflow devices in and out for space efficiency and manual device use.
The HALO ® PCS C18 is a positively charged surface chemistry designed to deliver improved peak shapes for basic compounds.
Long Read Sequencing (LRS) service employs cutting-edge technologies such as Oxford Nanopore and PacBio platforms for decoding complex genomes, completing transcriptomes, exploring metagenomes, and investigating structural variations with unmatched precision.
RNA sequencing is applied for in-depth analysis of whole transcriptomes, encompasses coding and non-coding RNAs (long ncRNA, small RNA, and circle RNA,etc.) for diverse research needs.
Whole exome sequencing allows for sequencing human and mouse exomes in an array of panel options, which facilitates research contexts and clinical contexts.
